Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Genexol-PM + cisplatin
- Development stage
- Unknown
- Lead developer
- Samyang Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Genexol-PM + cisplatin is a combination chemotherapy regimen consisting of Genexol-PM (a Cremophor EL-free polymeric micelle formulation of paclitaxel) and cisplatin. This combination allows for higher doses of paclitaxel compared to conventional formulations without significantly increased toxicity. The CrEL-free formulation reduces hypersensitivity reactions associated with conventional paclitaxel.
- Brand names
- GenexolPM
- Other names
- Genexol-PM + cisplatincremophor EL-free paclitaxel + cisplatin
02
Targets
DNA
Beyond the preview
Go deeper on Genexol-PM + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genexol-PM + cisplatin.